EOLSEvolus, Inc.
$7.00+2.6% 1Y
$7.00
$3.9452 weeks$9.30
Is the price fair?
What EOLS's price assumes
Evolus, Inc. did not earn a profit over the last twelve months, so it has no trailing P/E and the price is measured against sales instead: 1.45× revenue.
1.45
Price / sales · no P/E: the last twelve months did not end in a profit
- EV / sales
- 1.80
EV / sales
Details›
- EV / EBIToperating margin −5.9%: the multiple describes the denominator
- not meaningful
- EV / salesas of 2026-Q2
- 1.80
- Market capitalisation66.1 million shares, counted Jul 31, 2026
- $462M
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
Drug Manufacturers, Specialty & Generic
Ranks #33 of 39 by RyuScore